ISO 14155-2020医疗器械临床实验管理规范
VIP免费
Clinical investigation of medical
devices for human subjects — Good
clinical practice
Investigation clinique des dispositifs médicaux pour sujets humains —
Bonne pratique clinique
© ISO 2020
INTERNATIONAL
STANDARD
ISO
14155
Third edition
2020-07
Reference number
ISO 14155:2020(E)
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
ii © ISO 2020 – All rights reserved
COPYRIGHT PROTECTED DOCUMENT
© ISO 2020
Website: www.iso.org
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
Foreword ..........................................................................................................................................................................................................................................v
1 Scope ................................................................................................................................................................................................................................. 1
2 Normative references ...................................................................................................................................................................................... 1
..................................................................................................................................................................................... 1
4 Summary of good clinical practice (GCP) principles ....................................................................................................... 9
5 Ethical considerations .................................................................................................................................................................................10
........................................................................................................................................................................................................ 10
....................................................................................................................................10
.................................................................................................................... 10
.............................................................................................................. 11
5.5 Responsibilities ...................................................................................................................................................................................11
...................................................................................................11
................................................................................................................................................................................... 11
................................................................................................................................................. 11
................................................................................................... 12
................................................................................................... 12
..................................................................... 12
................................................................................................................................................................. 12
...............................................................................................................................................................................13
................................................................................................................................................................................... 13
..................................................................................................... 13
........................................................................................14
..............................................................................................15
................................................................................................................................ 17
...........................................................................................................................................................17
6 Clinical investigation planning ...........................................................................................................................................................17
........................................................................................................................................................................................................ 17
..............................................................................................................................................................................
...................................................................................................................................................................................
.....
............................................................................................................................
....................................................................................
............................................................................................................................................
.....................................................................................................................................................
............................................................................................................................................................ 20
................................................................................................................................................................................... 20
........................................................................................................................................................ 21
......................................................................................................................................................................................... 21
.................................................................................................................................................................................................... 21
...................................................................................................................................21
7 Clinical investigation conduct ..............................................................................................................................................................22
........................................................................................................................................................................................................ 22
....................................................................................................................................................... 22
..................................................................................................................................................22
.........................................................................................................................22
............................................................................................................. 22
7.4.2 Adverse events ................................................................................................................................................................ 23
......................................................................................................................................................23
..................................................23
...................................................................................... 24
7.5.1 Amendments .................................................................................................................................................................... 24
....................................................................................................................................... 24
© ISO 2020 – All rights reserved iii
Contents
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
摘要:
展开>>
收起<<
Clinicalinvestigationofmedicaldevicesforhumansubjects—GoodclinicalpracticeInvestigationcliniquedesdispositifsmédicauxpoursujetshumains—Bonnepratiqueclinique©ISO2020INTERNATIONALSTANDARDISO14155Thirdedition2020-07ReferencenumberISO14155:2020(E)CopyrightInternationalOrganizationforStandardizationProvi...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
ISO 14155-2020 医疗器械临床实验管理规范(中文版)VIP免费
2025-09-17 352 -
ISO 31000:2018 风险管理指南VIP免费
2025-10-28 303 -
ISO TS 10974-2018 评估有植入式医疗设备的患者进行磁共振成像的安全性VIP免费
2025-10-30 181 -
ISO TS 10974-2018 评估有植入式医疗设备的患者进行磁共振成像的安全性(中文版)
2025-10-30 240 -
ISO TS 10974-2018 评估有植入式医疗设备的患者进行磁共振成像的安全性_中英文版VIP专享
2025-10-30 141 -
ISO 10993-1-2018 医疗器械生物学评价 第1部分:风险管理过程中的评价与试验_中英文对照VIP专享
2025-11-03 152 -
ISO 14155-2026 人体医疗器械临床试验--良好临床实践VIP免费
2026-04-15 145 -
ISO IEC 17020 2026 Conformity assessment— Requirements for bodies performing inspectionVIP免费
2026-05-14 137 -
ISO 19011-2026-管理体系审核指南VIP免费
2026-06-03 110 -
ISO FDIS 9001_2026质量管理体系要求中英文版VIP免费
2026-07-02 364
作者:多多猪
分类:法规规范
价格:50质量币
属性:90 页
大小:1.33MB
格式:PDF
时间:2025-09-17

